03:05 PM EST - Cardiome Pharma Corp. : Announced that it has filed with the FDA's Office of Orphan Products Development a request for orphan drug designation for an oral formulation of vernakalant hydrochloride, under the FDA's Orphan Drug Act. The indication listed within the application is the prevention of post-operative atrial fibrillation in patients undergoing coronary artery bypass graft surgery. Cardiome Pharma Corp.
shares T.COM are trading unchanged at $0.90.
